Dr Reddy’s Laboratories has launched eszopiclone tablets (C-IV) 1 mg, 2 mg and 3 mg, a therapeutic equivalent generic version of Lunesta (eszopiclone) tablets C-IV in the US market on April 15, 2014, following the approval by the US FDA.

The Lunesta (eszopiclone) tablets C-IV brand and generic combined had US sales of approximately $887 million MAT for the most recent twelve months ending in January 2014 according to IMS Health.

Dr Reddy’s eszopiclone tablets (C-IV) 1 mg is available in bottle counts of 30.  Eszopiclone tablets (C-IV) 2 mg and 3 mg are available in bottle counts of 100.